T. Rowe Price Investment Management’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $619M | Buy |
3,583,546
+529,722
| +17% | +$91.4M | 0.39% | 72 |
|
|
2025
Q1 | $476M | Buy |
3,053,824
+328,278
| +12% | +$51.2M | 0.31% | 93 |
|
|
2024
Q4 | $375M | Buy |
2,725,546
+960,504
| +54% | +$132M | 0.23% | 116 |
|
|
2024
Q3 | $264M | Buy |
1,765,042
+1,734,478
| +5,675% | +$259M | 0.16% | 152 |
|
|
2024
Q2 | $4.17M | Sell |
30,564
-2,538,339
| -99% | -$346M | ﹤0.01% | 575 |
|
|
2024
Q1 | $388M | Sell |
2,568,903
-1,420,927
| -36% | -$215M | 0.24% | 111 |
|
|
2023
Q4 | $503M | Buy |
3,989,830
+5,327
| +0.1% | +$671K | 0.33% | 92 |
|
|
2023
Q3 | $373M | Buy |
3,984,503
+1,610
| +0% | +$151K | 0.26% | 108 |
|
|
2023
Q2 | $355M | Buy |
3,982,893
+509,427
| +15% | +$45.5M | 0.24% | 117 |
|
|
2023
Q1 | $372M | Buy |
3,473,466
+645,199
| +23% | +$69.2M | 0.27% | 104 |
|
|
2022
Q4 | $345M | Buy |
2,828,267
+796,087
| +39% | +$97.2M | 0.27% | 103 |
|
|
2022
Q3 | $210M | Buy |
+2,032,180
| New | +$210M | 0.17% | 140 |
|